Anaphylaxis Market
- According to DelveInsight's’ estimates, Anaphylaxis market in 7MM is expected to show a positive growth, during the forecast period (2023–2032), mainly attributed to new product launches, a decent pipeline of emerging therapies, as well as the ongoing clinical development.
- AstraZeneca, Aquestive Therapeutics, and others are some of the companies working in the Anaphylaxis market.
- Acalabrutinib, AQST-109, AQST-108, and others are some of the drugs in the Anaphylaxis treatment market.
Request for Sample Report @ Anaphylaxis market
DelveInsight's "Anaphylaxis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anaphylaxis, historical and forecasted epidemiology as well as the Anaphylaxis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Anaphylaxis market report provides current treatment practices, emerging drugs, Anaphylaxis market share of the individual therapies, current and forecasted Anaphylaxis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Anaphylaxis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Anaphylaxis market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Anaphylaxis Disease Treatment Market
The DelveInsight’s Anaphylaxis market report gives a thorough understanding of the Anaphylaxis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.
Anaphylaxis is a sudden and severe allergic reaction that affects the entire body and can be life-threatening. It is caused by the release of certain substances from mast cells and basophils. The condition develops rapidly and worsens quickly. Common symptoms include dizziness, difficulty breathing (such as rapid and shallow breaths), wheezing, rapid heartbeat, sweaty skin, confusion, anxiety, fainting, or loss of consciousness. Other allergy symptoms may also occur, such as itchy raised rashes (hives), nausea or vomiting, swelling (angioedema), or stomach pain.
Anaphylaxis happens when the immune system overreacts to a trigger. Common triggers include certain foods (like nuts, milk, fish, shellfish, eggs, and some fruits), medications (such as certain antibiotics and non-steroidal anti-inflammatory drugs like aspirin), insect stings (especially from wasps and bees), general anesthesia, contrast agents used in medical tests, latex, and others. In some cases, the trigger may not be apparent, and this is called idiopathic anaphylaxis.
Anaphylaxis Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Anaphylaxis.
To confirm the diagnosis, a blood test may be done to measure the level of a specific enzyme called tryptase, which can be elevated up to three hours after anaphylaxis. Allergy testing, either through skin tests or blood tests, may also be performed to help identify the trigger.
Differential diagnosis for anaphylaxis involves distinguishing it from other conditions that cause respiratory difficulties or circulatory collapse, including vasovagal reactions, globus hystericus, status asthmaticus, foreign body aspiration, pulmonary embolism, epiglottitis, myocardial infarction, carcinoid syndrome, hereditary angioedema, pheochromocytoma, and others. Vasovagal reactions do not present with upper airway obstruction, bronchospasm, abdominal cramps, itching, hives, or swelling. Pallor, syncope, sweating, and nausea are usually indicative of a vasovagal reaction but may occur in both conditions.
Anaphylaxis Treatment
It covers the details of conventional and current medical therapies available in the Anaphylaxis market for the treatment of the condition. It also provides Anaphylaxis treatment algorithms and guidelines in the United States, Europe, and Japan.
Anaphylaxis Epidemiology
The Anaphylaxis epidemiology section provides insights about the historical and current Anaphylaxis patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Anaphylaxis market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Anaphylaxis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
- According to available literature, Anaphylaxis affects equally both females and males.
- Yu et al. (2018) conducted a study titled “The Epidemiology of Anaphylaxis”, wherein the lifetime prevalence of anaphylaxis was estimated at 0.05–2% in the USA and approximately 3% in Europe.
- National Institute For Health And Care Excellence (NICE) (2015), stated that between March 2013 and February 2014 approximately 1 in 5 admissions to hospitals in England due to allergies were for an anaphylactic reaction (4070 out of 20,318). This was an increase of 9.9% compared to the previous year. The NICE CG134 guideline reported an available UK estimate that about 1 in 1,333 of the population of England had experienced anaphylaxis at some point in their lives. However, a systematic review published in 2013 estimated that 1 in 300 people in Europe were affected by anaphylaxis at some point in their lives.
Country Wise- Anaphylaxis Epidemiology
The epidemiology segment also provides the Anaphylaxis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Anaphylaxis Recent Developments
- In March 2025, the FDA approved the expanded use of ARS Pharmaceuticals' Neffy nasal spray for severe allergic reactions in patients weighing between 15 and 30 kg. First approved in August, Neffy offers an alternative to EpiPen and other epinephrine autoinjectors, designed for use at the first sign of a severe allergic reaction to prevent life-threatening conditions like anaphylaxis.
Anaphylaxis Drug Chapters
The drug chapter segment of the Anaphylaxis market report encloses the detailed analysis of Anaphylaxis marketed drugs and late-stage (Phase-III and Phase-II) Anaphylaxis pipeline drugs. It also helps to understand the Anaphylaxis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Marketed Anaphylaxis Drugs
The report provides the details of the marketed products/off-label treatments available for Anaphylaxis treatment.
Emerging Anaphylaxis Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Anaphylaxis treatment.
Acalabrutinib: AstraZeneca
Acalabrutinib is being investigated by AstraZeneca, Calquence (acalabrutinib; previously known as ACP-196) is a selective inhibitor of BTK. Calquence binds covalently to BTK, thereby inhibits its activity. The trial is an open-label study designed to determine the ability acalabrutinib to prevent signs and symptoms of anaphylaxis during an oral food challenge in food-allergic adult. Currently the trial is in Phase II and the primary outcome will measure change in the highest dose of peanut or tree nut that is tolerated during oral food challenge before and after taking acalabrutinib. The study is expected to complete by December 2023.
AQST-108: Aquestive Therapeutics
AQST-108, is being investigated by Aquestive Therapeutics. It is a “first of its kind” oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of anaphylaxis. AQST-108-SF is composed of the prodrug dipivefrin, which is contained within a unique polymeric matrix of Aquestive’s Pharmfilm technology. The company submitted an IND for AQST-108-SF to the FDA in June 2020. In august 2020, the US FDA granted Fast Track designation to AQST-108-SF. The Phase I study featured a 4-treatment crossover design that compared the pharmacokinetics, safety and pharmacodynamics of epinephrine administered in a sublingual film to that of epinephrine administered via both subcutaneous and intramuscular injections in 28 healthy adult subjects. The company is on track to request a pre-IND meeting for AQST-108 with the FDA in 2022 and plan to disclose the indication and path forward for development, once they have received feedback from the agency.
AQST-109: Aquestive Therapeutics
AQST-109 is a next generation prodrug sublingual film formulation of epinephrine that Aquestive intends to develop for treatment of allergic reactions including anaphylaxis. In vitro tests and preclinical studies indicate that AQST-109-SF has the potential to absorb more extensively, convert more rapidly to systemic epinephrine, utilize less drug and provide a unique profile when compared to AQST-108-SF. In March 2022, the company reported a continued rapid absorption of AQST-109 as exemplified by the data from Parts 1 and 2 of the EPIPHAST study. In April 2022, Aquestive reported positive topline results from Part 2 of the EPIPHAST study for its AQST-109 epinephrine oral film. Aquestive commenced Part 3 of the EPIPHAST study for its AQST-109 product candidate in April 2022 and expects to complete Part 3 by the end of the second quarter of 2022.
Anaphylaxis Market Outlook
The Anaphylaxis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Anaphylaxis market trends by analyzing the impact of current Anaphylaxis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Anaphylaxis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Anaphylaxis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Anaphylaxis market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Findings
This section includes a glimpse of the Anaphylaxis market in 7MM.
The United States: Anaphylaxis Market Outlook
This section provides the total Anaphylaxis market size and market size by therapies in the United States.
EU-5 Countries: Anaphylaxis Market Outlook
The total Anaphylaxis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Anaphylaxis Market Outlook
The total Anaphylaxis market size and market size by therapies in Japan is also mentioned.
Anaphylaxis Drugs Uptake
This section focuses on the rate of uptake of the potential Anaphylaxis drugs recently launched in the Anaphylaxis market or expected to get launched in the market during the study period 2019-2032. The analysis covers Anaphylaxis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Anaphylaxis Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Anaphylaxis market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Anaphylaxis Pipeline Development Activities
The Anaphylaxis market report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Anaphylaxis companies involved in developing targeted therapeutics.
Pipeline Development Activities
The Anaphylaxis market report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Anaphylaxis emerging therapies.
Reimbursement Scenario in Anaphylaxis
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current Anaphylaxis market trends, we take KOLs and SMEs ' opinion working in the Anaphylaxis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Anaphylaxis market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Anaphylaxis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
| Report Metrics | Details |
| Study Period | 2019 to 2032 |
| Forecast Period | 2023 to 2032 |
| Anaphylaxis CAGR | |
| Anaphylaxis Market Size | USD XX million in 2021 |
| Key Anaphylaxis Companies | AstraZeneca, Aquestive Therapeutics, and others. |
Scope of the Anaphylaxis Market Report
- The report covers the descriptive overview of Anaphylaxis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Anaphylaxis epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Anaphylaxis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Anaphylaxis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Anaphylaxis market
Anaphylaxis Market Report Highlights
- In the coming years, the Anaphylaxis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The Anaphylaxis companies and academics are working to assess challenges and seek opportunities that could influence Anaphylaxis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Anaphylaxis. The launch of emerging therapies will significantly impact the Anaphylaxis market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Anaphylaxis
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Anaphylaxis Market Report Insights
- Anaphylaxis Patient Population
- Anaphylaxis Therapeutic Approaches
- Anaphylaxis Pipeline Analysis
- Anaphylaxis Market Size and Trends
- Anaphylaxis Market Opportunities
- Impact of upcoming Anaphylaxis Therapies
Anaphylaxis Report Key Strengths
- 10 Years Forecast
- 7MM Coverage
- Anaphylaxis Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Anaphylaxis Market
- Anaphylaxis Drugs Uptake
Anaphylaxis Market Report Assessment
- Current Anaphylaxis Treatment Practices
- Anaphylaxis Unmet Needs
- Anaphylaxis Pipeline Product Profiles
- Anaphylaxis Market Attractiveness
- Anaphylaxis Market Drivers and Barriers
Key Questions
Anaphylaxis Market Insights:
- What was the Anaphylaxis drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the total Anaphylaxis market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Anaphylaxis market size during the forecast period (2019-2032)?
- At what CAGR, the Anaphylaxis market is expected to grow by 7MM during the forecast period (2019-2032)?
- What would be the Anaphylaxis market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the Anaphylaxis market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the unmet needs affect the Anaphylaxis market dynamics and subsequent analysis of the associated trends?
Anaphylaxis Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of the Anaphylaxis?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Anaphylaxis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Anaphylaxis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Anaphylaxis?
- Out of all 7MM countries, which country would have the highest prevalent population of Anaphylaxis during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Anaphylaxis treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Anaphylaxis in the USA, Europe, and Japan?
- What are the Anaphylaxis marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many Anaphylaxis companies are developing therapies for the treatment of Anaphylaxis?
- How many therapies are in-development by each company for Anaphylaxis treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Anaphylaxis treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Anaphylaxis therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
- What are the ongoing Anaphylaxis clinical trials and their status?
- What are the current challenges faced in Anaphylaxis drug development?
- What are the key designations that have been granted for the emerging therapies for Anaphylaxis?
- What are the global historical and forecasted Anaphylaxis market?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Anaphylaxis market
- To understand the future market competition in the Anaphylaxis market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Anaphylaxis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Anaphylaxis market
- To understand the future market competition in the Anaphylaxis market